Key result
In a retrospective analysis of 95 patients with unprotected left main coronary artery disease, overall survival was not significantly different between those treated with bare-metal stents (74.2%) and drug-eluting stents (85.1%) (p=0.111).
Why the study?
Does bare-metal stenting improve long-term safety outcomes compared to drug-eluting stents in patients with unprotected left main coronary artery disease?
Observational (n=95)
No
Does bare-metal stenting improve long-term safety outcomes compared to drug-eluting stents in patients with unprotected left main coronary artery disease?
Absolute Event Rate: 74.2% vs 85.1%
p-value: p=0.111
This review highlights ongoing concerns with drug-eluting stents in left main disease, such as late stent thrombosis, and argues for further analysis of remote-stage outcomes with bare-metal stents.
In the past, coronary artery bypass graft surgery has been applied to revascularization for unprotected left main coronary artery (ULMCA) disease. In recent years, due to the advent of drug-eluting stents (DES), restenosis rates have decreased in comparison to conventional bare-metal stents (BMS), and the range of applications of percutaneous coronary intervention (PCI) for ULMCA disease has been expanded. However, even if DES is used, outcomes of PCI for distal left main coronary artery bifurcation lesions are not sufficient. Moreover, problems specific to DES, such as late stent thrombosis and late catch-up phenomenon, have been identified. There are still unknown points regarding remote-stage outcomes of DES. Thus, further investigation is needed on PCI for ULMCA disease, along with further analysis of remote-stage outcomes of BMS.
No takes yet. Share an insight, caveat, or question.
Kaneko et al. (2011) conducted an observational in Unprotected left main coronary artery (ULMCA) disease (n=95). Bare-metal stents vs. Drug-eluting stents was evaluated on Overall survival (p=0.111). In a retrospective analysis of 95 patients with unprotected left main coronary artery disease, overall survival was not significantly different between those treated with bare-metal stents (74.2%) and drug-eluting stents (85.1%) (p=0.111).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: